Cargando…
Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285755/ https://www.ncbi.nlm.nih.gov/pubmed/25614824 http://dx.doi.org/10.1530/EDM-14-0081 |
_version_ | 1782351594021453824 |
---|---|
author | Boronat, Mauro Sánchez-Hernández, Rosa M Rodríguez-Cordero, Julia Jiménez-Ortega, Angelines Nóvoa, Francisco J |
author_facet | Boronat, Mauro Sánchez-Hernández, Rosa M Rodríguez-Cordero, Julia Jiménez-Ortega, Angelines Nóvoa, Francisco J |
author_sort | Boronat, Mauro |
collection | PubMed |
description | Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin delivered through CSII therapy. However, even for patients treated with CSII, exaggerated postmeal hyperglycemic excursions and late postabsorptive hypoglycemia can still constitute a therapeutic challenge. Two female patients with type 1 diabetes who began treatment with CSII required to increase their previous breakfast insulin-to-carbohydrate ratio in order to achieve postprandial glycemic goals. However, they simultaneously presented recurrent episodes of late hypoglycemia several hours after breakfast bolus. Advancing the timing of the bolus was ineffective and bothersome for patients. In both cases, the best therapeutic option was to set a basal insulin rate of zero units per hour during 6 h after breakfast. Even so, they need to routinely take a midmorning snack with 10–20 g of carbohydrates to avoid late postabsorptive hypoglycemia. They have been using this insulin schedule for about 3 years without complications. The action of prandial insulin delivered through insulin pumps can be inappropriately delayed for the requirements of some patients. Although suspension of basal rate can be an acceptable therapeutic alternative for them, these cases demonstrate that new strategies to improve the bioavailability of prandial insulin infused through CSII are still needed. LEARNING POINTS: CSII remains the most physiologically suitable system of insulin delivery available today. Additionally, the duration of action of prandial insulin delivered through insulin pumps can be excessively prolonged in some patients with type 1 diabetes. These patients can present recurrent late episodes of hypoglycemia several hours after the administration of insulin boluses. The routine suspension of basal insulin for several hours, leaving meal bolus to cover both prandial and basal insulin requirements, can be a therapeutic option for these subjects. |
format | Online Article Text |
id | pubmed-4285755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42857552015-01-22 Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump Boronat, Mauro Sánchez-Hernández, Rosa M Rodríguez-Cordero, Julia Jiménez-Ortega, Angelines Nóvoa, Francisco J Endocrinol Diabetes Metab Case Rep Unusual Effects of Medical Treatment Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin delivered through CSII therapy. However, even for patients treated with CSII, exaggerated postmeal hyperglycemic excursions and late postabsorptive hypoglycemia can still constitute a therapeutic challenge. Two female patients with type 1 diabetes who began treatment with CSII required to increase their previous breakfast insulin-to-carbohydrate ratio in order to achieve postprandial glycemic goals. However, they simultaneously presented recurrent episodes of late hypoglycemia several hours after breakfast bolus. Advancing the timing of the bolus was ineffective and bothersome for patients. In both cases, the best therapeutic option was to set a basal insulin rate of zero units per hour during 6 h after breakfast. Even so, they need to routinely take a midmorning snack with 10–20 g of carbohydrates to avoid late postabsorptive hypoglycemia. They have been using this insulin schedule for about 3 years without complications. The action of prandial insulin delivered through insulin pumps can be inappropriately delayed for the requirements of some patients. Although suspension of basal rate can be an acceptable therapeutic alternative for them, these cases demonstrate that new strategies to improve the bioavailability of prandial insulin infused through CSII are still needed. LEARNING POINTS: CSII remains the most physiologically suitable system of insulin delivery available today. Additionally, the duration of action of prandial insulin delivered through insulin pumps can be excessively prolonged in some patients with type 1 diabetes. These patients can present recurrent late episodes of hypoglycemia several hours after the administration of insulin boluses. The routine suspension of basal insulin for several hours, leaving meal bolus to cover both prandial and basal insulin requirements, can be a therapeutic option for these subjects. Bioscientifica Ltd 2015-01-01 2015 /pmc/articles/PMC4285755/ /pubmed/25614824 http://dx.doi.org/10.1530/EDM-14-0081 Text en © 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/deed.en_GB) . |
spellingShingle | Unusual Effects of Medical Treatment Boronat, Mauro Sánchez-Hernández, Rosa M Rodríguez-Cordero, Julia Jiménez-Ortega, Angelines Nóvoa, Francisco J Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
title | Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
title_full | Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
title_fullStr | Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
title_full_unstemmed | Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
title_short | Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
title_sort | suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump |
topic | Unusual Effects of Medical Treatment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285755/ https://www.ncbi.nlm.nih.gov/pubmed/25614824 http://dx.doi.org/10.1530/EDM-14-0081 |
work_keys_str_mv | AT boronatmauro suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump AT sanchezhernandezrosam suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump AT rodriguezcorderojulia suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump AT jimenezortegaangelines suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump AT novoafranciscoj suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump |